Asparaginase is a key tool used in regimens to treat both pediatric and young adult patients with acute lymphoblastic leukemia (ALL). There are side effects associated with the agent, however, and in a study presented by Orgel et al at the 2022 ASCO Annual Meeting, a group of researchers sought to determine what factors may increase the likelihood of the development of asparaginase-associated toxicities.
